Editas Medicine, Inc. Common Stock

Day range

$2.30 – $2.45

Open

$2.44

Prev close

$2.49

Volume

1.31M

Market cap

$382.41M

Shares out

153.58M

P/E

—

P/S

8.14

P/B

3.63

P/FCF

—

ROE

-70.2%

ROA

-31.1%

Debt/Equity

0.53

Div yield

0.00%

As of Oct 22, 2026

• Investor communicationsOct 8, 2026

  EDIT-401 is an experimental, potentially best-in-class in vivo gene editing medicine for the treatment of hyperlipidemia. In preclinical studies, EDIT-401 demonstrated approximately 90 percent or greater mean reduction in multiple atherogenic lipoproteins, including LDL-C, Lp(a), and ApoB, in non-human primates.

• Board of directorsAug 5, 2026

  On August 3, 2026, Elliott Levy, M.D., a member of the Board of Directors (the "Board") of the Company who was serving as a class I director, resigned from the Board, effective August 4, 2026. The resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

• Equity activityMay 26, 2026

  Each Underwritten Share is being offered and sold together with an accompanying Common Stock Warrant at a combined public offering price of $2.25. The Underwriters have agreed to purchase each Underwritten Share and accompanying Common Stock Warrant from the Company pursuant to the Underwriting Agreement at a combined price of $2.1150. The Company estimates that the net proceeds from the offering will be approximately $117.0 million, after deducting underwriting discounts and commissions and estimated offering expenses.

• Equity activityMay 26, 2026

  the Company may offer and sell shares of its common stock, $0.0001 par value per share (the "Common Stock"), from time to time through TD Cowen, as agent, under an "at-the-market" offering program. As of May 26, 2026, the Company had issued and sold an aggregate of 14,327,365 shares of its Common Stock under its "at-the-market" offering program with TD Cowen for aggregate gross sale proceeds of $43.9 million

• Business developmentsMay 26, 2026

  The Company also received pre-IND feedback from the U.S. Food and Drug Administration ('FDA') on its nonclinical package, CMC plans, and study design to support an Investigational New Drug Application ('IND') for EDIT-401, which the Company believes provides optionality for submitting an IND supportive of the Company's anticipated clinical development strategy.

• CRSPCRISPR Therapeutics AG-1.20%
• NTLAIntellia Therapeutics, Inc+0.45%
• NTLAIntellia Therapeutics, Inc+0.45%
• CRSPCRISPR Therapeutics AG-1.20%
• BEAMBeam Therapeutics Inc. Common Stock-2.08%

Days to cover

9.3

Short interest

37.11M

Avg volume

3.97M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
  positiveZacks Investment Research· Oct 9, 2026
• Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
  positiveGlobeNewswire Inc.· Sep 8, 2026
• Lyora Therapeutics Launches With Seed Funding to Propel Its Biologically Validated Pipeline of Genetic Medicines to Treat Inherited Retinal Diseases
  neutralGlobeNewswire Inc.· Jul 14, 2026
• Gene Editing Therapeutics: Transforming Biopharmaceuticals with 12.5% CAGR Growth Forecast
  positiveGlobeNewswire Inc.· Jul 3, 2026
• Global CRISPR-Based Drug Development Platforms Market to Reach USD 0.79 Billion by 2031: Precision Medicine and Gene Therapy Drive Growth
  positiveGlobeNewswire Inc.· Jul 3, 2026